Send us Feedback

Generex Biotechnology (GNBT)
QUOTE AND NEWS
Generex Biotechnology (GNBT) Prepares to Submit Positive Data From Study with MetControl
StreetInsider.com  Jun 29 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Generex+Biotechnology+%28GNBT%29+Prepares+to+Submit+Positive+Data+From+Study+with+MetControl/4759942.html for the full story.
Generex (GNBT) Subsidiary Developed New Vaccine Technology Which Could Speed Up Flu Vaccine Availability
StreetInsider.com  Jun 26 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Generex+%28GNBT%29+Subsidiary+Developed+New+Vaccine+Technology+Which+Could+Speed+Up+Flu+Vaccine+Availability/4757240.html for the full story.
Generex's Net Loss Widens On Interest Expense
TheStreet.com  Jun 10 
Despite surging third quarter revenue, the drug company's net loss increased to $0.08 per share.
Generex Biotechnology (GNBT) Announces Positive Study Data On Two Products
StreetInsider.com  Jun 9 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Generex+Biotechnology+%28GNBT%29+Announces+Positive+Study+Data+On+Two+Products/4717432.html for the full story.
Biotech Stocks: Drug stocks inch lower while broader market gains
MarketWatch  Jun 4 
Drug stocks inch lower in afternoon trading, although Novavax is soaring about 50% on news related to its swine-flu vaccine technology.
Vaccine makers get boost from flu scare
MarketWatch  May 21 
Shares of niche makers of vaccines and anti-viral drugs have been on fire since the H1N1 flu first made headlines last month, but are these fledgling companies really in a position to cash in on a possible pandemic?
Chuck Jaffe: Pigs will get slaughtered on swine-flu stocks
MarketWatch  Apr 30 
Investors might be able to get a bump out of big-name stocks touched by the swine-flu crisis, but plays for penny-stocks are nothing but a siren’s song, likely to leave the typical speculator screaming like, well, a stuck pig.
Niche antiviral drugmakers rocket on flu news
MarketWatch  Apr 27 
Shares of niche makers of antiviral products saw shares rocket in early trading Monday on news that the world could be facing a global pandemic of the swine flu virus. Leading the pack was Biota Holdings Ltd , with U.S.-traded shares shooting up...
Generex (GNBT) - decent buy signal
Trade Radar  Nov 17 
Here is a view of what the system looks like. Note the red peak in the lower chart. This indicates that a low has been hit. The horizontal green line intersects the red peak. Where it intersects on the right side of the peak (the trailing...
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
See All
BULLS: REASONS TO BUY

 
100% agree
 
Pain Free Insulin

 
0% agree
 
Massive Opportunity

See All
BEARS: REASONS TO SELL
Bears: Reasons To Sell
Feeling Bearish? Be the first to explain why this would make a poor investment
See All (0)
more ▼EditWIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 
GNBT AT A GLANCE
P/E ►-2.36 
EV/EBITDA ►-11.8 
ROA ►-83.7%LOW
ROE ►-256.2%VERY LOW
Debt to Equity ►6.56VERY HIGH
Current Ratio ►0.708LOW
Interest Coverage Ratio ►-1.41AVG
 
 
 
 
 
 
 
 
Please install Flash Player to view this chart.



[edit] References

Retrieved from "http://www.wikinvest.com/stock/Generex_Biotechnology_(GNBT)"
 
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki